Eupraxia Pharmaceuticals (EPRX) Free Cash Flow (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Free Cash Flow data on file, last reported at -$9.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 68.32% year-over-year to -$9.8 million in Q1 2026; TTM through Mar 2026 was -$33.1 million, a 11.15% decrease from a year earlier, with the FY2025 full-year figure at -$29.1 million, up 3.18% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$9.8 million, up from -$10.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for EPRX reached as high as -$4.3 million in Q2 2023 and fell as low as -$10.7 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$6.9 million across 4 years, with a median of -$6.1 million in 2024.
• Across the five-year window, Free Cash Flow tumbled 80.16% in 2024 and soared 56.18% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$6.1 million in 2023, then fell by 1.23% to -$6.1 million in 2024, then tumbled by 74.56% to -$10.7 million in 2025, then climbed by 8.33% to -$9.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$9.8 million in Q1 2026, -$10.7 million in Q4 2025, and -$4.4 million in Q3 2025.